人工关节市场格局分析

Group 1 - The artificial joint orthopedic market is experiencing steady growth, with the market size in China reaching approximately 45 billion RMB in 2022 and projected to exceed 180 billion RMB by 2030, driven by demographic changes and increased prevalence of joint diseases [3][4]. - The aging population in China is a significant factor for market growth, with the proportion of individuals aged 65 and above expected to rise from 10.5% in 2015 to 15.64% in 2024, leading to increased demand for joint surgeries and related products [4]. - The introduction of centralized procurement policies has led to a significant increase in the domestic market share of Chinese brands, with local brands capturing 68% of the market after two rounds of procurement, compared to over 70% held by foreign brands before [8][12]. Group 2 - Major domestic companies in the artificial joint sector include Weigao Orthopedics, Aikang Medical, and Chunzhi Medical, all of which have faced challenges due to procurement policies but are adapting by focusing on innovation and market share expansion [13][18]. - The average prices for hip and knee joints have drastically decreased due to centralized procurement, with hip joint prices dropping from 35,000 RMB to around 7,000 RMB, and knee joints from 32,000 RMB to 5,000 RMB, resulting in an average price reduction of 82% [12]. - Despite short-term impacts on revenue and profit margins due to procurement policies, the long-term strategy of "price for volume" is expected to help companies expand market share and drive domestic replacement of imported products [18][21].